Sign in

    Tully on for Steven Willey

    Managing Director and Senior Equity Research Analyst at Stifel

    Stephen Willey is a Managing Director and Senior Equity Research Analyst at Stifel, specializing in the biotechnology sector within healthcare. He covers a diverse range of biotechnology companies and has established a solid performance track record, with a 71% buy rating ratio and 7.8% average return noted on TipRanks and an overall analyst ranking around 3000. Willey began his career as a Research Scientist at ImClone Systems and Research Associate at Mount Sinai School of Medicine, later joining Thomas Weisel Partners before the 2010 acquisition by Stifel. He holds an undergraduate degree from the University of New Hampshire, an MBA from New York University, an M.S. from the University of Rhode Island, and is registered with FINRA.

    Tully on for Steven Willey's questions to Compass Therapeutics (CMPX) leadership

    Tully on for Steven Willey's questions to Compass Therapeutics (CMPX) leadership • Q2 2025

    Question

    Asked about the patient demographics in the tivesimig trial and whether they are representative of historical trials, given the low death rate. Also inquired about the safety profile of CTX-10726 and plans to present preclinical data.

    Answer

    The company responded that while cross-trial comparisons are difficult without the final data, the study's randomization was stratified by key prognostic variables, ensuring the treatment arms are well-balanced. Preclinical data for CTX-10726 will be presented at a scientific conference later in the year.

    Ask Fintool Equity Research AI